Find A Clinical Trial

Disease Type: Gynecologic

Trial ID DK210 (EGFR)
Sponsor ID DEKA Biosciences

Dose-finding Phase 1 Trial: Evaluating Safety and Biomarkers Using DK210 (EGFR) for Inoperable Locally Advanced and/or Metastatic EGFR+ Tumors With Progressive Disease Failing Systemic Therapy

Trial ID 21457
Sponsor ID Artistry-7

(ALKS 4230-007/GOG-3063) A Phase 3, Multicenter, Open-Label, Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator’s Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARTISTRY-7)

Principal Investigator
Robert L. Marsh, MD
5 Locations
Trial ID 21308
Sponsor ID Zentalis Pharmaceuticals

A Phase 1/2 Dose-Escalation and Dose-Expansion Study of ZN‑c3 in Combination with Niraparib in Subjects with Platinum-Resistant Ovarian Cancer

1 Location
Trial ID 21253
Sponsor ID FLORA-5

A Phase 3, Double-Blind, Placebo-Controlled, Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) in Patients with Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma(FLORA-5)

Principal Investigator
Robert L. Marsh, MD
3 Locations
Trial ID STRO-002-GM2
Sponsor ID Sutro Biopharma

A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor alpha Antibody Drug Conjugate (ADC), in Combination with Bevacizumab in Patients with Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers).

1 Location
Trial ID 20298
Sponsor ID

Phase 2 Study of VS-6766 (Dual RAK/MEK Inhibitor) Alone and in Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)

Principal Investigator
Mitul Gandhi, MD
5 Locations